Clinical Trials Directory

Trials / Unknown

UnknownNCT00179816

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

High-Dose Chemotherapy With Tandem Peripheral Blood Stem Cell (PBSC) Rescue for the Treatment of High-Risk Pediatric Solid Tumors.

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors.

Detailed description

Significant advances have been made in recent years in the treatment of solid tumors of childhood. However, much of the improvement in survival has been made in low stage and localized disease. Of significance is the fact that the improvements have come in up-front remission rates without translation into significantly high event-free survival(EFS) or overall survival (OS). This is despite the fact that these tumors as a whole are largely chemotherapy responsive. Recent advances in the understanding of the biology of hematopoeitic stem cells have driven the design of treatment regimens that allow for dose intensification without unacceptable hematologic toxicity. Protocol development has focused on active agents that have a broad range between hematologic and non-hematologic toxicities. This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors. This study utilizes PBSC to limit the risk of tumor cell contamination while retaining prompt hematologic recovery from these highly intensified treatments.

Conditions

Interventions

TypeNameDescription
DRUGHigh-Dose Chemotherapy with Tandem PBSC Rescue.Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.

Timeline

Start date
1999-04-01
Primary completion
2012-09-01
Completion
2012-09-01
First posted
2005-09-16
Last updated
2010-10-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00179816. Inclusion in this directory is not an endorsement.